

AMENDMENTS TO THE SPECIFICATION

Please amend the Specification at page 11, line 1 as follows:

Oligos Names	5' to 3' Sequences
FVIII-L2-2I-S	AAC AAT GCC ATT GAA CCA AGA CGT CGT GGA GGT CGA CGA GAA ATA ACT CGT <u>(SEQ ID NO:1)</u>
FVIII-L2-2I-AS	ACG AGT TAT TTC TCG TCG ACC TCC ACG ACG TCT TGG TTC AAT GGC ATT GTT <u>(SEQ ID NO:2)</u>
FVIII-N538-S	AAT ATG GAG AGA GAT CTA GCT TCA GG <u>(SEQ ID NO:3)</u>
FVIII-L0-New-AS	CTC GTC GAC GAC GTC TTG GTT CAA TGG <u>(SEQ ID NO:4)</u>

Table I: Oligonucleotides used for creating FVIII-L2 vectors

Please amend the Specification at page 11, line 20 as follows:

Oligos Names	Sequences
β -Glob-NheI-S	CTA GCTAGC GTGAGTTGGGGACCCTTG <u>(SEQ ID NO:5)</u>
β -Glob-Not I-AS	ATAGTTA GCGGCCGC TGTAGGAAAAAGAAGAAGGC <u>(SEQ ID NO:6)</u>

Table II: Oligonucleotides used for β-globin cloning